Daniel Bensen - Mar 30, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Mar 30, 2023
Transactions value $
-$68,045
Form type
4
Date filed
4/3/2023, 08:07 PM
Previous filing
Mar 29, 2023
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $1.22K +2K +0.38% $0.61* 530K Mar 30, 2023 Direct
transaction TYRA Common Stock Sale -$32K -2K -0.38% $16.01 528K Mar 30, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $244 +400 +0.08% $0.61* 528K Mar 31, 2023 Direct
transaction TYRA Common Stock Sale -$6.4K -400 -0.08% $16.00 528K Mar 31, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $1.22K +2K +0.38% $0.61* 530K Apr 3, 2023 Direct
transaction TYRA Common Stock Sale -$32.3K -2K -0.38% $16.16 528K Apr 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2K -0.86% $0.00 232K Mar 30, 2023 Common Stock 2K $0.61 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -400 -0.17% $0.00 231K Mar 31, 2023 Common Stock 400 $0.61 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2K -0.86% $0.00 229K Apr 3, 2023 Common Stock 2K $0.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.